Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes, Gestational | 59 | 2024 | 340 | 10.060 |
Why?
|
Autism Spectrum Disorder | 17 | 2024 | 163 | 7.340 |
Why?
|
Diabetes Mellitus, Type 2 | 52 | 2024 | 748 | 6.440 |
Why?
|
Air Pollution | 11 | 2024 | 42 | 6.060 |
Why?
|
Insulin Resistance | 33 | 2023 | 133 | 5.910 |
Why?
|
Air Pollutants | 12 | 2024 | 52 | 5.630 |
Why?
|
Insulin-Secreting Cells | 13 | 2018 | 20 | 4.310 |
Why?
|
Prenatal Exposure Delayed Effects | 13 | 2024 | 160 | 4.300 |
Why?
|
Pregnancy | 79 | 2024 | 1494 | 3.920 |
Why?
|
Insulin | 38 | 2023 | 205 | 3.640 |
Why?
|
Female | 131 | 2024 | 12608 | 3.080 |
Why?
|
Humans | 158 | 2024 | 17611 | 3.080 |
Why?
|
Hypoglycemic Agents | 22 | 2022 | 268 | 3.050 |
Why?
|
Blood Glucose | 35 | 2023 | 341 | 2.800 |
Why?
|
Mexican Americans | 18 | 2019 | 45 | 2.640 |
Why?
|
Pregnancy in Diabetics | 8 | 2018 | 21 | 2.580 |
Why?
|
Hispanic Americans | 33 | 2019 | 404 | 2.450 |
Why?
|
Body Mass Index | 27 | 2023 | 958 | 2.430 |
Why?
|
Adult | 89 | 2024 | 7598 | 2.330 |
Why?
|
Particulate Matter | 10 | 2024 | 29 | 2.240 |
Why?
|
Male | 77 | 2024 | 10008 | 2.150 |
Why?
|
Thiazolidinediones | 13 | 2013 | 52 | 2.140 |
Why?
|
Weight Gain | 6 | 2019 | 173 | 2.020 |
Why?
|
Child, Preschool | 19 | 2024 | 1409 | 1.870 |
Why?
|
Breast Feeding | 5 | 2020 | 133 | 1.860 |
Why?
|
Child | 26 | 2024 | 2474 | 1.720 |
Why?
|
Retrospective Studies | 29 | 2024 | 2447 | 1.710 |
Why?
|
Cohort Studies | 35 | 2024 | 2570 | 1.680 |
Why?
|
Glucose Tolerance Test | 32 | 2020 | 107 | 1.660 |
Why?
|
Analgesia, Epidural | 2 | 2023 | 4 | 1.620 |
Why?
|
Labor, Obstetric | 2 | 2023 | 5 | 1.620 |
Why?
|
Environmental Pollutants | 2 | 2023 | 46 | 1.610 |
Why?
|
Metformin | 5 | 2022 | 57 | 1.600 |
Why?
|
Maternal Exposure | 7 | 2024 | 60 | 1.590 |
Why?
|
Multiple Sclerosis | 6 | 2020 | 97 | 1.570 |
Why?
|
Adiposity | 7 | 2019 | 66 | 1.560 |
Why?
|
Autistic Disorder | 4 | 2024 | 100 | 1.480 |
Why?
|
California | 26 | 2024 | 2284 | 1.480 |
Why?
|
Polymorphism, Single Nucleotide | 19 | 2022 | 373 | 1.450 |
Why?
|
Obesity | 15 | 2022 | 837 | 1.450 |
Why?
|
Overweight | 6 | 2022 | 269 | 1.410 |
Why?
|
Depression | 2 | 2024 | 502 | 1.370 |
Why?
|
Hypertension | 10 | 2023 | 500 | 1.340 |
Why?
|
Asthma | 2 | 2023 | 385 | 1.250 |
Why?
|
Adipokines | 2 | 2018 | 5 | 1.240 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 2 | 2019 | 64 | 1.220 |
Why?
|
Mothers | 5 | 2023 | 105 | 1.210 |
Why?
|
Glucose Intolerance | 8 | 2022 | 45 | 1.200 |
Why?
|
Risk Factors | 39 | 2024 | 3325 | 1.200 |
Why?
|
Pre-Eclampsia | 3 | 2024 | 40 | 1.090 |
Why?
|
Adolescent | 21 | 2024 | 3651 | 1.070 |
Why?
|
Environmental Exposure | 7 | 2024 | 116 | 1.060 |
Why?
|
Exercise Therapy | 4 | 2019 | 71 | 1.000 |
Why?
|
Nitrogen Dioxide | 4 | 2023 | 13 | 0.970 |
Why?
|
European Continental Ancestry Group | 9 | 2021 | 529 | 0.950 |
Why?
|
Gastroplasty | 3 | 2022 | 9 | 0.950 |
Why?
|
C-Reactive Protein | 2 | 2018 | 58 | 0.930 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 4 | 2019 | 197 | 0.920 |
Why?
|
Young Adult | 19 | 2024 | 2427 | 0.900 |
Why?
|
Longitudinal Studies | 11 | 2019 | 710 | 0.900 |
Why?
|
Anxiety | 1 | 2024 | 150 | 0.880 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2024 | 107 | 0.860 |
Why?
|
Awards and Prizes | 1 | 2023 | 9 | 0.860 |
Why?
|
Chromans | 9 | 2007 | 10 | 0.850 |
Why?
|
Mentoring | 2 | 2019 | 26 | 0.810 |
Why?
|
Follow-Up Studies | 15 | 2020 | 1210 | 0.800 |
Why?
|
Genetic Variation | 11 | 2017 | 77 | 0.800 |
Why?
|
Islets of Langerhans | 8 | 2024 | 12 | 0.770 |
Why?
|
Diabetes Mellitus, Type 1 | 5 | 2018 | 121 | 0.760 |
Why?
|
Genetic Predisposition to Disease | 12 | 2024 | 368 | 0.760 |
Why?
|
Pancreatitis | 1 | 2022 | 50 | 0.760 |
Why?
|
Ozone | 3 | 2019 | 11 | 0.750 |
Why?
|
Incidence | 11 | 2024 | 1255 | 0.740 |
Why?
|
Hypothalamus | 2 | 2022 | 3 | 0.720 |
Why?
|
Middle Aged | 39 | 2019 | 7911 | 0.720 |
Why?
|
Genome-Wide Association Study | 11 | 2024 | 243 | 0.710 |
Why?
|
Parents | 2 | 2019 | 296 | 0.710 |
Why?
|
PPAR gamma | 4 | 2015 | 10 | 0.690 |
Why?
|
African Continental Ancestry Group | 3 | 2018 | 162 | 0.690 |
Why?
|
Mass Screening | 2 | 2024 | 661 | 0.690 |
Why?
|
Leptin | 2 | 2018 | 29 | 0.690 |
Why?
|
Hospitalization | 3 | 2023 | 797 | 0.680 |
Why?
|
Glucose | 6 | 2023 | 30 | 0.670 |
Why?
|
Prediabetic State | 2 | 2013 | 56 | 0.660 |
Why?
|
Child of Impaired Parents | 1 | 2019 | 33 | 0.660 |
Why?
|
Pediatric Obesity | 3 | 2024 | 81 | 0.640 |
Why?
|
Emergency Service, Hospital | 2 | 2019 | 358 | 0.630 |
Why?
|
Disease Progression | 6 | 2024 | 264 | 0.630 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2024 | 531 | 0.620 |
Why?
|
Aged | 25 | 2022 | 6095 | 0.610 |
Why?
|
Interleukin-6 | 1 | 2018 | 25 | 0.610 |
Why?
|
Infant | 5 | 2023 | 1171 | 0.590 |
Why?
|
Cytomegalovirus | 1 | 2017 | 3 | 0.590 |
Why?
|
Herpesvirus 4, Human | 1 | 2017 | 6 | 0.590 |
Why?
|
Hippocampus | 3 | 2024 | 6 | 0.590 |
Why?
|
Infant, Newborn | 13 | 2024 | 844 | 0.590 |
Why?
|
Blood Pressure | 9 | 2019 | 298 | 0.580 |
Why?
|
Energy Intake | 2 | 2014 | 101 | 0.580 |
Why?
|
Antibodies, Viral | 1 | 2017 | 65 | 0.570 |
Why?
|
Postpartum Period | 5 | 2020 | 94 | 0.560 |
Why?
|
Motor Activity | 3 | 2015 | 212 | 0.500 |
Why?
|
Oceanic Ancestry Group | 1 | 2014 | 33 | 0.480 |
Why?
|
Asian Continental Ancestry Group | 1 | 2014 | 90 | 0.470 |
Why?
|
Health Status Disparities | 2 | 2014 | 146 | 0.450 |
Why?
|
Arteriosclerosis | 2 | 2004 | 20 | 0.450 |
Why?
|
Luminescent Measurements | 1 | 2013 | 1 | 0.440 |
Why?
|
Adiponectin | 3 | 2010 | 21 | 0.440 |
Why?
|
Immunoassay | 1 | 2013 | 8 | 0.440 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2013 | 12 | 0.440 |
Why?
|
Diet, High-Fat | 1 | 2013 | 5 | 0.430 |
Why?
|
Hepatitis B | 1 | 2013 | 42 | 0.420 |
Why?
|
Cholesterol, LDL | 6 | 2016 | 119 | 0.410 |
Why?
|
Exercise | 6 | 2022 | 489 | 0.410 |
Why?
|
Tunica Intima | 4 | 2009 | 9 | 0.400 |
Why?
|
Prevalence | 3 | 2024 | 884 | 0.400 |
Why?
|
Non-alcoholic Fatty Liver Disease | 2 | 2024 | 8 | 0.390 |
Why?
|
Vehicle Emissions | 3 | 2024 | 23 | 0.390 |
Why?
|
Diabetes Mellitus | 5 | 2011 | 487 | 0.390 |
Why?
|
Glucose Clamp Technique | 10 | 2014 | 13 | 0.390 |
Why?
|
United States | 8 | 2024 | 3956 | 0.390 |
Why?
|
Logistic Models | 4 | 2019 | 926 | 0.380 |
Why?
|
Diet | 4 | 2022 | 365 | 0.380 |
Why?
|
Severity of Illness Index | 3 | 2022 | 454 | 0.380 |
Why?
|
Carotid Artery Diseases | 2 | 2007 | 12 | 0.380 |
Why?
|
Obstetric Labor Complications | 2 | 2017 | 13 | 0.370 |
Why?
|
Contraceptives, Oral | 3 | 2007 | 26 | 0.370 |
Why?
|
Absorptiometry, Photon | 5 | 2015 | 50 | 0.360 |
Why?
|
Medroxyprogesterone Acetate | 2 | 2011 | 15 | 0.360 |
Why?
|
Magnetic Resonance Imaging | 4 | 2024 | 103 | 0.360 |
Why?
|
Risk | 4 | 2017 | 516 | 0.330 |
Why?
|
Pregnancy Complications | 3 | 2020 | 196 | 0.320 |
Why?
|
Body Composition | 4 | 2014 | 82 | 0.320 |
Why?
|
Genotype | 6 | 2019 | 227 | 0.320 |
Why?
|
Triglycerides | 5 | 2010 | 86 | 0.310 |
Why?
|
HLA-DRB1 Chains | 2 | 2019 | 13 | 0.310 |
Why?
|
Sunlight | 2 | 2018 | 13 | 0.300 |
Why?
|
Electric Impedance | 3 | 2014 | 7 | 0.300 |
Why?
|
Socioeconomic Factors | 4 | 2017 | 630 | 0.300 |
Why?
|
Proportional Hazards Models | 8 | 2019 | 709 | 0.290 |
Why?
|
Medroxyprogesterone | 1 | 2007 | 2 | 0.290 |
Why?
|
Membrane Proteins | 2 | 2019 | 38 | 0.290 |
Why?
|
Homeostasis | 3 | 2016 | 11 | 0.290 |
Why?
|
Carotid Arteries | 3 | 2009 | 9 | 0.290 |
Why?
|
Vitamin D | 2 | 2018 | 76 | 0.290 |
Why?
|
Cholesterol, HDL | 5 | 2016 | 79 | 0.280 |
Why?
|
Lipids | 1 | 2007 | 77 | 0.280 |
Why?
|
Walking | 2 | 2019 | 85 | 0.280 |
Why?
|
Risk Assessment | 6 | 2016 | 1097 | 0.270 |
Why?
|
Time Factors | 10 | 2017 | 1086 | 0.270 |
Why?
|
Body Weight | 5 | 2013 | 219 | 0.270 |
Why?
|
African Americans | 5 | 2019 | 472 | 0.260 |
Why?
|
Metabolic Syndrome | 3 | 2015 | 80 | 0.260 |
Why?
|
Phenotype | 11 | 2014 | 149 | 0.250 |
Why?
|
Quantitative Trait, Heritable | 2 | 2021 | 8 | 0.240 |
Why?
|
Cues | 1 | 2024 | 9 | 0.240 |
Why?
|
Pandemics | 2 | 2024 | 287 | 0.240 |
Why?
|
RNA-Binding Proteins | 2 | 2018 | 6 | 0.240 |
Why?
|
Quality of Life | 3 | 2019 | 507 | 0.240 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2016 | 171 | 0.230 |
Why?
|
Genome, Mitochondrial | 1 | 2024 | 2 | 0.230 |
Why?
|
Caveolin 1 | 2 | 2015 | 2 | 0.230 |
Why?
|
Cesarean Section | 1 | 2004 | 30 | 0.230 |
Why?
|
Cross-Sectional Studies | 4 | 2016 | 1322 | 0.220 |
Why?
|
Aircraft | 1 | 2023 | 3 | 0.220 |
Why?
|
Oxytocin | 1 | 2023 | 4 | 0.220 |
Why?
|
Obesity, Morbid | 2 | 2017 | 120 | 0.220 |
Why?
|
Transcription Factors | 2 | 2024 | 19 | 0.220 |
Why?
|
Analgesics | 1 | 2023 | 27 | 0.220 |
Why?
|
Gestational Age | 3 | 2020 | 111 | 0.220 |
Why?
|
Carbon | 1 | 2023 | 3 | 0.220 |
Why?
|
Manganese | 1 | 2023 | 3 | 0.220 |
Why?
|
Prostatic Neoplasms | 2 | 2018 | 262 | 0.210 |
Why?
|
Streptococcal Infections | 1 | 2023 | 22 | 0.210 |
Why?
|
Fasting | 7 | 2013 | 48 | 0.210 |
Why?
|
Vitamins | 1 | 2023 | 64 | 0.210 |
Why?
|
Pregnancy Trimester, First | 2 | 2019 | 39 | 0.210 |
Why?
|
Treatment Outcome | 5 | 2019 | 1259 | 0.200 |
Why?
|
Drug Therapy, Combination | 2 | 2013 | 114 | 0.200 |
Why?
|
Environmental Monitoring | 2 | 2019 | 26 | 0.200 |
Why?
|
Biomarkers | 2 | 2013 | 301 | 0.190 |
Why?
|
Acute Disease | 1 | 2022 | 142 | 0.190 |
Why?
|
Anti-Bacterial Agents | 1 | 2023 | 140 | 0.190 |
Why?
|
Case-Control Studies | 4 | 2018 | 1115 | 0.190 |
Why?
|
Aged, 80 and over | 5 | 2019 | 1900 | 0.180 |
Why?
|
Kidney | 2 | 2019 | 52 | 0.180 |
Why?
|
Maternal Age | 1 | 2020 | 77 | 0.180 |
Why?
|
Social Support | 2 | 2019 | 203 | 0.180 |
Why?
|
Fructose | 1 | 2020 | 5 | 0.180 |
Why?
|
Self Report | 2 | 2019 | 251 | 0.180 |
Why?
|
Dietary Sugars | 1 | 2020 | 6 | 0.180 |
Why?
|
Animals | 6 | 2024 | 259 | 0.170 |
Why?
|
Anxiety Disorders | 1 | 2020 | 91 | 0.170 |
Why?
|
APOBEC-1 Deaminase | 1 | 2019 | 1 | 0.170 |
Why?
|
Thiazoles | 4 | 2002 | 9 | 0.170 |
Why?
|
DNA, Viral | 1 | 2019 | 17 | 0.170 |
Why?
|
Hepatitis B virus | 1 | 2019 | 20 | 0.170 |
Why?
|
Lipase | 1 | 2019 | 1 | 0.170 |
Why?
|
Aspartate Aminotransferases | 1 | 2019 | 13 | 0.170 |
Why?
|
Alanine Transaminase | 1 | 2019 | 21 | 0.170 |
Why?
|
Ultrasonography, Prenatal | 2 | 2001 | 8 | 0.170 |
Why?
|
C-Peptide | 3 | 2017 | 6 | 0.170 |
Why?
|
Glycated Hemoglobin A | 5 | 2021 | 216 | 0.170 |
Why?
|
Fetal Development | 1 | 2019 | 14 | 0.170 |
Why?
|
Pregnancy Trimesters | 2 | 2019 | 30 | 0.170 |
Why?
|
Transcription Factor 7-Like 2 Protein | 2 | 2017 | 13 | 0.160 |
Why?
|
Kidney Calculi | 1 | 2019 | 6 | 0.160 |
Why?
|
Mutation | 1 | 2019 | 128 | 0.160 |
Why?
|
Genetic Linkage | 3 | 2012 | 7 | 0.160 |
Why?
|
Alleles | 4 | 2021 | 84 | 0.160 |
Why?
|
Cholesterol | 2 | 2010 | 106 | 0.160 |
Why?
|
Amino Acid Substitution | 3 | 2015 | 7 | 0.160 |
Why?
|
Mice | 5 | 2024 | 68 | 0.160 |
Why?
|
Odds Ratio | 2 | 2019 | 671 | 0.160 |
Why?
|
Primary Health Care | 1 | 2024 | 766 | 0.160 |
Why?
|
Receptors, Androgen | 1 | 2018 | 9 | 0.150 |
Why?
|
Life Style | 1 | 2020 | 332 | 0.150 |
Why?
|
Glomerular Filtration Rate | 1 | 2019 | 153 | 0.150 |
Why?
|
Fatty Acids, Nonesterified | 4 | 2009 | 12 | 0.150 |
Why?
|
Vitamin D-Binding Protein | 1 | 2018 | 4 | 0.150 |
Why?
|
Tunica Media | 3 | 2009 | 5 | 0.150 |
Why?
|
Reference Values | 2 | 2013 | 91 | 0.150 |
Why?
|
Pragmatic Clinical Trials as Topic | 1 | 2018 | 57 | 0.150 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2018 | 51 | 0.150 |
Why?
|
Estrogen Receptor beta | 1 | 2017 | 10 | 0.150 |
Why?
|
Polymorphism, Genetic | 1 | 2018 | 62 | 0.150 |
Why?
|
Vitamin D Deficiency | 1 | 2018 | 21 | 0.150 |
Why?
|
Liver | 4 | 2024 | 32 | 0.150 |
Why?
|
Anthropometry | 3 | 2015 | 66 | 0.150 |
Why?
|
Epigenesis, Genetic | 2 | 2021 | 25 | 0.150 |
Why?
|
Epstein-Barr Virus Nuclear Antigens | 1 | 2017 | 2 | 0.150 |
Why?
|
Exosomes | 1 | 2017 | 2 | 0.150 |
Why?
|
Hygiene | 1 | 2017 | 4 | 0.150 |
Why?
|
Hypoxia | 1 | 2017 | 8 | 0.150 |
Why?
|
RNA, Long Noncoding | 1 | 2017 | 5 | 0.150 |
Why?
|
Reproductive Physiological Phenomena | 1 | 2017 | 3 | 0.150 |
Why?
|
Patient Selection | 2 | 2018 | 190 | 0.150 |
Why?
|
Emigrants and Immigrants | 1 | 2017 | 27 | 0.140 |
Why?
|
Asphyxia | 1 | 2017 | 3 | 0.140 |
Why?
|
Exercise Tolerance | 1 | 2017 | 13 | 0.140 |
Why?
|
Sodium Chloride, Dietary | 2 | 2017 | 9 | 0.140 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2019 | 179 | 0.140 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2017 | 56 | 0.140 |
Why?
|
Proline | 2 | 2015 | 5 | 0.140 |
Why?
|
Alanine | 2 | 2015 | 6 | 0.140 |
Why?
|
Premenopause | 2 | 2007 | 24 | 0.140 |
Why?
|
Diet, Diabetic | 3 | 1998 | 9 | 0.140 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2016 | 20 | 0.130 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2015 | 1 | 0.130 |
Why?
|
Surveys and Questionnaires | 2 | 2017 | 1309 | 0.130 |
Why?
|
Regression Analysis | 4 | 2014 | 297 | 0.130 |
Why?
|
Chi-Square Distribution | 2 | 2013 | 154 | 0.130 |
Why?
|
Pancreatic Neoplasms | 1 | 2016 | 67 | 0.130 |
Why?
|
Ethnic Groups | 2 | 2019 | 485 | 0.130 |
Why?
|
Prospective Studies | 5 | 2013 | 1267 | 0.120 |
Why?
|
Complement Activation | 1 | 2015 | 1 | 0.120 |
Why?
|
Lectins | 1 | 2015 | 1 | 0.120 |
Why?
|
Glycoproteins | 1 | 2015 | 2 | 0.120 |
Why?
|
Complement System Proteins | 1 | 2015 | 4 | 0.120 |
Why?
|
Immunoglobulin M | 1 | 2015 | 8 | 0.120 |
Why?
|
Premature Birth | 1 | 2017 | 137 | 0.120 |
Why?
|
Vincristine | 1 | 1994 | 1 | 0.120 |
Why?
|
Prednisone | 1 | 1994 | 5 | 0.120 |
Why?
|
Adipose Tissue | 3 | 2009 | 58 | 0.120 |
Why?
|
Sex Factors | 4 | 2020 | 643 | 0.120 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1994 | 9 | 0.120 |
Why?
|
Bariatric Surgery | 1 | 2017 | 128 | 0.120 |
Why?
|
Receptor, Melatonin, MT2 | 1 | 2014 | 1 | 0.120 |
Why?
|
Metabolic Clearance Rate | 1 | 2014 | 4 | 0.120 |
Why?
|
Primary Prevention | 1 | 2014 | 73 | 0.120 |
Why?
|
Osteoporosis | 1 | 2015 | 74 | 0.120 |
Why?
|
Risk Reduction Behavior | 1 | 2014 | 108 | 0.120 |
Why?
|
Myocardial Infarction | 1 | 2016 | 238 | 0.110 |
Why?
|
Glucagon-Like Peptide 1 | 1 | 2013 | 4 | 0.110 |
Why?
|
Liraglutide | 1 | 2013 | 5 | 0.110 |
Why?
|
Waist-Hip Ratio | 2 | 2011 | 23 | 0.110 |
Why?
|
Arginine | 1 | 2013 | 12 | 0.110 |
Why?
|
Congenital Abnormalities | 3 | 2000 | 26 | 0.110 |
Why?
|
Gastrectomy | 1 | 2014 | 46 | 0.110 |
Why?
|
Laparoscopy | 1 | 2014 | 48 | 0.110 |
Why?
|
Research Design | 2 | 1999 | 374 | 0.110 |
Why?
|
Drug Monitoring | 1 | 2013 | 20 | 0.110 |
Why?
|
Stroke | 1 | 2016 | 311 | 0.110 |
Why?
|
Patient-Centered Care | 1 | 2015 | 197 | 0.110 |
Why?
|
Dietary Proteins | 1 | 2013 | 20 | 0.110 |
Why?
|
Dietary Carbohydrates | 1 | 2013 | 27 | 0.110 |
Why?
|
Cell Line, Tumor | 3 | 2018 | 8 | 0.110 |
Why?
|
Gastric Bypass | 1 | 2014 | 71 | 0.110 |
Why?
|
Multifactorial Inheritance | 2 | 2024 | 20 | 0.110 |
Why?
|
Time-to-Treatment | 1 | 2013 | 18 | 0.110 |
Why?
|
Reproducibility of Results | 1 | 2013 | 381 | 0.100 |
Why?
|
Antiviral Agents | 1 | 2013 | 94 | 0.100 |
Why?
|
Chromosomes, Human, Pair 20 | 1 | 2012 | 1 | 0.100 |
Why?
|
Sensitivity and Specificity | 1 | 2013 | 304 | 0.100 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 2012 | 7 | 0.100 |
Why?
|
Oxidoreductases, N-Demethylating | 1 | 2012 | 2 | 0.100 |
Why?
|
Postnatal Care | 1 | 2012 | 21 | 0.100 |
Why?
|
Histone Demethylases | 1 | 2012 | 3 | 0.100 |
Why?
|
Prenatal Care | 2 | 2012 | 128 | 0.100 |
Why?
|
Age Factors | 3 | 2017 | 917 | 0.100 |
Why?
|
Patient Readmission | 1 | 2014 | 163 | 0.100 |
Why?
|
Progestins | 2 | 2010 | 25 | 0.100 |
Why?
|
Genetic Association Studies | 3 | 2017 | 33 | 0.100 |
Why?
|
Contraceptive Agents, Female | 1 | 2011 | 12 | 0.100 |
Why?
|
Hepatocyte Nuclear Factor 4 | 2 | 2007 | 4 | 0.090 |
Why?
|
Promoter Regions, Genetic | 2 | 2007 | 15 | 0.090 |
Why?
|
Intra-Abdominal Fat | 1 | 2011 | 14 | 0.090 |
Why?
|
Waist Circumference | 1 | 2011 | 38 | 0.090 |
Why?
|
Survival Rate | 3 | 2016 | 260 | 0.090 |
Why?
|
Contraception | 1 | 2010 | 25 | 0.090 |
Why?
|
Glucose-6-Phosphatase | 1 | 2009 | 2 | 0.090 |
Why?
|
Protein-Serine-Threonine Kinases | 1 | 2009 | 3 | 0.090 |
Why?
|
Protein Tyrosine Phosphatases | 1 | 2009 | 1 | 0.080 |
Why?
|
Placebos | 2 | 2007 | 21 | 0.080 |
Why?
|
Surgical Staplers | 1 | 2009 | 1 | 0.080 |
Why?
|
Electrocoagulation | 1 | 2009 | 3 | 0.080 |
Why?
|
Proto-Oncogene Proteins | 1 | 2009 | 32 | 0.080 |
Why?
|
Leg | 1 | 2009 | 3 | 0.080 |
Why?
|
Blood Loss, Surgical | 1 | 2009 | 3 | 0.080 |
Why?
|
Thigh | 1 | 2009 | 11 | 0.080 |
Why?
|
Amputation | 1 | 2009 | 11 | 0.080 |
Why?
|
Calpain | 1 | 2009 | 1 | 0.080 |
Why?
|
Genetic Loci | 2 | 2019 | 55 | 0.080 |
Why?
|
GTP-Binding Protein beta Subunits | 1 | 2008 | 1 | 0.080 |
Why?
|
Haplotypes | 3 | 2019 | 34 | 0.080 |
Why?
|
Contraceptives, Oral, Combined | 2 | 2006 | 5 | 0.080 |
Why?
|
Cell Proliferation | 2 | 2018 | 19 | 0.080 |
Why?
|
Hypertension, Renal | 1 | 2007 | 4 | 0.080 |
Why?
|
Pedigree | 2 | 2014 | 60 | 0.070 |
Why?
|
Hyperinsulinism | 2 | 2001 | 9 | 0.070 |
Why?
|
Linear Models | 2 | 2019 | 231 | 0.070 |
Why?
|
Genotyping Techniques | 2 | 2018 | 26 | 0.070 |
Why?
|
Albuminuria | 1 | 2007 | 38 | 0.070 |
Why?
|
Quantitative Trait Loci | 2 | 2021 | 36 | 0.070 |
Why?
|
Mice, Inbred C57BL | 2 | 2024 | 17 | 0.070 |
Why?
|
TCF Transcription Factors | 1 | 2007 | 10 | 0.070 |
Why?
|
Safety | 1 | 2007 | 41 | 0.070 |
Why?
|
Pregnancy Trimester, Third | 2 | 1999 | 17 | 0.070 |
Why?
|
Apoptosis | 2 | 2018 | 10 | 0.070 |
Why?
|
Parity | 4 | 2005 | 74 | 0.070 |
Why?
|
Weight Loss | 2 | 2022 | 303 | 0.070 |
Why?
|
Pilot Projects | 3 | 2017 | 218 | 0.060 |
Why?
|
Metabolic Networks and Pathways | 1 | 2024 | 6 | 0.060 |
Why?
|
Genome, Human | 2 | 2021 | 32 | 0.060 |
Why?
|
Food | 1 | 2024 | 30 | 0.060 |
Why?
|
Enteroendocrine Cells | 1 | 2024 | 1 | 0.060 |
Why?
|
Endothelial Cells | 1 | 2024 | 2 | 0.060 |
Why?
|
Single-Cell Analysis | 1 | 2024 | 2 | 0.060 |
Why?
|
Adipocytes | 1 | 2024 | 4 | 0.060 |
Why?
|
Epigenomics | 1 | 2024 | 5 | 0.060 |
Why?
|
Chromatin | 1 | 2024 | 5 | 0.060 |
Why?
|
Fibrosis | 1 | 2024 | 7 | 0.060 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2003 | 2 | 0.060 |
Why?
|
Protein Biosynthesis | 1 | 2003 | 2 | 0.060 |
Why?
|
Peripheral Arterial Disease | 1 | 2024 | 13 | 0.060 |
Why?
|
Diabetic Nephropathies | 1 | 2024 | 26 | 0.060 |
Why?
|
Inflammation | 1 | 2024 | 62 | 0.060 |
Why?
|
Streptococcus agalactiae | 1 | 2023 | 8 | 0.050 |
Why?
|
Antibiotic Prophylaxis | 1 | 2023 | 14 | 0.050 |
Why?
|
Gliosis | 1 | 2022 | 1 | 0.050 |
Why?
|
Coronary Artery Disease | 1 | 2024 | 134 | 0.050 |
Why?
|
Recurrence | 2 | 2020 | 186 | 0.050 |
Why?
|
Carotid Artery, Common | 1 | 2002 | 2 | 0.050 |
Why?
|
Insurance, Health | 1 | 2024 | 181 | 0.050 |
Why?
|
Likelihood Functions | 1 | 2002 | 44 | 0.050 |
Why?
|
Puerperal Disorders | 1 | 2002 | 9 | 0.050 |
Why?
|
Chromosomes, Human, Pair 7 | 1 | 2001 | 3 | 0.050 |
Why?
|
Physical Chromosome Mapping | 1 | 2021 | 1 | 0.050 |
Why?
|
Texas | 2 | 2014 | 35 | 0.050 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 34 | 0.050 |
Why?
|
Coronary Disease | 1 | 2002 | 181 | 0.050 |
Why?
|
Cluster Analysis | 1 | 2001 | 89 | 0.040 |
Why?
|
Sex Distribution | 1 | 2001 | 190 | 0.040 |
Why?
|
Multivariate Analysis | 1 | 2002 | 568 | 0.040 |
Why?
|
Signal Transduction | 2 | 2011 | 30 | 0.040 |
Why?
|
Age Distribution | 1 | 2001 | 246 | 0.040 |
Why?
|
Immunosuppressive Agents | 1 | 2020 | 20 | 0.040 |
Why?
|
Diet Surveys | 1 | 2020 | 57 | 0.040 |
Why?
|
Organ Size | 1 | 2020 | 15 | 0.040 |
Why?
|
Linkage Disequilibrium | 2 | 2013 | 30 | 0.040 |
Why?
|
Sequence Analysis, DNA | 1 | 2019 | 30 | 0.040 |
Why?
|
gamma-Glutamyltransferase | 1 | 2019 | 3 | 0.040 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2019 | 26 | 0.040 |
Why?
|
HLA-A3 Antigen | 1 | 2019 | 3 | 0.040 |
Why?
|
HLA-B7 Antigen | 1 | 2019 | 3 | 0.040 |
Why?
|
Histones | 1 | 2019 | 1 | 0.040 |
Why?
|
Histone Code | 1 | 2019 | 1 | 0.040 |
Why?
|
Models, Biological | 1 | 1999 | 30 | 0.040 |
Why?
|
Liver Neoplasms | 1 | 2019 | 40 | 0.040 |
Why?
|
Intrauterine Devices, Copper | 2 | 1998 | 5 | 0.040 |
Why?
|
Occupational Diseases | 1 | 1999 | 41 | 0.040 |
Why?
|
Embryonic and Fetal Development | 1 | 1998 | 3 | 0.040 |
Why?
|
Fetus | 1 | 1998 | 6 | 0.040 |
Why?
|
Gravidity | 1 | 1998 | 8 | 0.040 |
Why?
|
Patient Education as Topic | 2 | 2015 | 211 | 0.040 |
Why?
|
Occupational Exposure | 1 | 1999 | 67 | 0.040 |
Why?
|
Body Constitution | 1 | 1998 | 39 | 0.040 |
Why?
|
Gene Silencing | 1 | 2018 | 1 | 0.040 |
Why?
|
RNA, Small Interfering | 1 | 2018 | 1 | 0.040 |
Why?
|
Androgen Receptor Antagonists | 1 | 2018 | 2 | 0.040 |
Why?
|
Anilides | 1 | 2018 | 3 | 0.040 |
Why?
|
Tosyl Compounds | 1 | 2018 | 3 | 0.040 |
Why?
|
Cell Cycle | 1 | 2018 | 4 | 0.040 |
Why?
|
Public Health | 1 | 1999 | 80 | 0.040 |
Why?
|
Ultrasonography | 2 | 2009 | 35 | 0.040 |
Why?
|
Nitriles | 1 | 2018 | 7 | 0.040 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2018 | 3 | 0.040 |
Why?
|
Ultraviolet Rays | 1 | 2018 | 6 | 0.040 |
Why?
|
Mice, Knockout | 2 | 2011 | 15 | 0.040 |
Why?
|
Estrogen Replacement Therapy | 1 | 1998 | 99 | 0.040 |
Why?
|
Colorado | 2 | 2014 | 163 | 0.040 |
Why?
|
Asian Americans | 1 | 2019 | 176 | 0.040 |
Why?
|
Heterografts | 1 | 2017 | 1 | 0.040 |
Why?
|
Mice, Nude | 1 | 2017 | 2 | 0.040 |
Why?
|
Cell Movement | 1 | 2017 | 5 | 0.040 |
Why?
|
Dietary Supplements | 1 | 2018 | 87 | 0.040 |
Why?
|
Analysis of Variance | 2 | 1995 | 159 | 0.040 |
Why?
|
Neoplasm Invasiveness | 1 | 2017 | 78 | 0.040 |
Why?
|
Apgar Score | 1 | 2017 | 5 | 0.040 |
Why?
|
Pravastatin | 1 | 2016 | 2 | 0.040 |
Why?
|
Rosuvastatin Calcium | 1 | 2016 | 4 | 0.040 |
Why?
|
Deoxycytidine | 1 | 2016 | 7 | 0.040 |
Why?
|
Lovastatin | 1 | 2016 | 7 | 0.040 |
Why?
|
Simvastatin | 1 | 2016 | 11 | 0.040 |
Why?
|
Sodium-Potassium-Exchanging ATPase | 1 | 1996 | 2 | 0.030 |
Why?
|
Myocardium | 1 | 1996 | 6 | 0.030 |
Why?
|
Carrier Proteins | 1 | 1996 | 13 | 0.030 |
Why?
|
Isoenzymes | 1 | 1996 | 4 | 0.030 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 44 | 0.030 |
Why?
|
Guidelines as Topic | 1 | 2016 | 40 | 0.030 |
Why?
|
Abnormalities, Drug-Induced | 1 | 1995 | 15 | 0.030 |
Why?
|
Pregnancy Outcome | 2 | 2010 | 154 | 0.030 |
Why?
|
Drug Prescriptions | 1 | 2016 | 151 | 0.030 |
Why?
|
Spirometry | 1 | 2015 | 65 | 0.030 |
Why?
|
Self Efficacy | 1 | 2015 | 68 | 0.030 |
Why?
|
Motor Vehicles | 1 | 2015 | 1 | 0.030 |
Why?
|
Pelvic Bones | 1 | 2015 | 5 | 0.030 |
Why?
|
Microscopy, Fluorescence | 1 | 2015 | 1 | 0.030 |
Why?
|
HT29 Cells | 1 | 2015 | 1 | 0.030 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2015 | 2 | 0.030 |
Why?
|
MCF-7 Cells | 1 | 2015 | 4 | 0.030 |
Why?
|
Serum | 1 | 2015 | 3 | 0.030 |
Why?
|
Protein Binding | 1 | 2015 | 9 | 0.030 |
Why?
|
Genome | 1 | 2014 | 3 | 0.030 |
Why?
|
Gene Expression Regulation | 1 | 2014 | 23 | 0.030 |
Why?
|
Family Health | 2 | 2007 | 44 | 0.030 |
Why?
|
Sample Size | 1 | 2014 | 29 | 0.030 |
Why?
|
Motivation | 1 | 2015 | 130 | 0.030 |
Why?
|
Bone Density | 1 | 2015 | 92 | 0.030 |
Why?
|
Eating | 1 | 1994 | 37 | 0.030 |
Why?
|
Poisson Distribution | 1 | 2014 | 88 | 0.030 |
Why?
|
Angiotensin II | 1 | 1993 | 2 | 0.030 |
Why?
|
Databases, Factual | 1 | 2014 | 309 | 0.030 |
Why?
|
Brachytherapy | 1 | 2013 | 5 | 0.030 |
Why?
|
Health Maintenance Organizations | 1 | 2014 | 417 | 0.030 |
Why?
|
Residence Characteristics | 1 | 2015 | 248 | 0.030 |
Why?
|
Lod Score | 1 | 2012 | 1 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2013 | 237 | 0.030 |
Why?
|
Genetic Markers | 1 | 2011 | 25 | 0.020 |
Why?
|
Disease Management | 1 | 2012 | 135 | 0.020 |
Why?
|
Translational Medical Research | 1 | 2011 | 35 | 0.020 |
Why?
|
Immunoblotting | 2 | 2003 | 2 | 0.020 |
Why?
|
Glyburide | 1 | 2010 | 7 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2003 | 129 | 0.020 |
Why?
|
Double-Blind Method | 2 | 2002 | 155 | 0.020 |
Why?
|
Infant, Newborn, Diseases | 2 | 2001 | 34 | 0.020 |
Why?
|
Receptor, Insulin | 1 | 2009 | 6 | 0.020 |
Why?
|
Blood Transfusion | 1 | 2009 | 3 | 0.020 |
Why?
|
Hemostasis, Surgical | 1 | 2009 | 2 | 0.020 |
Why?
|
Electronic Health Records | 1 | 2014 | 681 | 0.020 |
Why?
|
Postoperative Care | 1 | 2009 | 20 | 0.020 |
Why?
|
Probability | 1 | 2009 | 79 | 0.020 |
Why?
|
Tolbutamide | 2 | 2000 | 3 | 0.020 |
Why?
|
Thymine | 1 | 2008 | 1 | 0.020 |
Why?
|
Cytosine | 1 | 2008 | 2 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2009 | 102 | 0.020 |
Why?
|
Siblings | 1 | 2007 | 12 | 0.020 |
Why?
|
San Francisco | 1 | 2007 | 64 | 0.020 |
Why?
|
Kidney Function Tests | 1 | 2007 | 22 | 0.020 |
Why?
|
Models, Genetic | 1 | 2007 | 23 | 0.020 |
Why?
|
HLA Antigens | 1 | 2007 | 4 | 0.020 |
Why?
|
Los Angeles | 1 | 2007 | 139 | 0.020 |
Why?
|
Postprandial Period | 1 | 2007 | 6 | 0.020 |
Why?
|
Pharmacogenetics | 1 | 2005 | 15 | 0.020 |
Why?
|
Cardiovascular Diseases | 1 | 2011 | 598 | 0.020 |
Why?
|
DNA Primers | 1 | 2004 | 7 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2004 | 49 | 0.010 |
Why?
|
Chromatography, Gel | 1 | 2003 | 1 | 0.010 |
Why?
|
3T3-L1 Cells | 1 | 2003 | 1 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2003 | 3 | 0.010 |
Why?
|
Proteins | 1 | 2003 | 16 | 0.010 |
Why?
|
Medical Records | 1 | 2002 | 100 | 0.010 |
Why?
|
Skinfold Thickness | 1 | 2001 | 18 | 0.010 |
Why?
|
Microsatellite Repeats | 1 | 2001 | 10 | 0.010 |
Why?
|
Chromosome Mapping | 1 | 2001 | 17 | 0.010 |
Why?
|
Infant, Small for Gestational Age | 1 | 2001 | 57 | 0.010 |
Why?
|
Intensive Care Units, Neonatal | 1 | 2001 | 41 | 0.010 |
Why?
|
Central Nervous System | 1 | 2000 | 2 | 0.010 |
Why?
|
Musculoskeletal Abnormalities | 1 | 2000 | 3 | 0.010 |
Why?
|
Abnormalities, Multiple | 1 | 2000 | 11 | 0.010 |
Why?
|
Sulfonylurea Compounds | 1 | 2000 | 24 | 0.010 |
Why?
|
Heart Defects, Congenital | 1 | 2000 | 37 | 0.010 |
Why?
|
Air Pollutants, Radioactive | 1 | 1999 | 1 | 0.010 |
Why?
|
Carcinogens, Environmental | 1 | 1999 | 1 | 0.010 |
Why?
|
Uranium | 1 | 1999 | 1 | 0.010 |
Why?
|
Half-Life | 1 | 1999 | 5 | 0.010 |
Why?
|
Mining | 1 | 1999 | 2 | 0.010 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 1999 | 3 | 0.010 |
Why?
|
Radon | 1 | 1999 | 3 | 0.010 |
Why?
|
Causality | 1 | 1999 | 40 | 0.010 |
Why?
|
Statistics as Topic | 1 | 1999 | 64 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 1999 | 351 | 0.010 |
Why?
|
Contraindications | 1 | 1998 | 14 | 0.010 |
Why?
|
Fetal Diseases | 1 | 1998 | 8 | 0.010 |
Why?
|
Morbidity | 1 | 1998 | 59 | 0.010 |
Why?
|
Carotid Stenosis | 1 | 1998 | 7 | 0.010 |
Why?
|
Forecasting | 1 | 1998 | 75 | 0.010 |
Why?
|
Prognosis | 1 | 1999 | 606 | 0.010 |
Why?
|
Heart Septum | 1 | 1996 | 1 | 0.010 |
Why?
|
Ouabain | 1 | 1996 | 1 | 0.010 |
Why?
|
Sodium-Calcium Exchanger | 1 | 1996 | 1 | 0.010 |
Why?
|
Heart Atria | 1 | 1996 | 3 | 0.010 |
Why?
|
Biological Transport | 1 | 1996 | 2 | 0.010 |
Why?
|
Azetidines | 1 | 1996 | 2 | 0.010 |
Why?
|
Tissue Donors | 1 | 1996 | 7 | 0.010 |
Why?
|
Sodium | 1 | 1996 | 12 | 0.010 |
Why?
|
Tissue Distribution | 1 | 1996 | 6 | 0.010 |
Why?
|
Heart Ventricles | 1 | 1996 | 17 | 0.010 |
Why?
|
Potassium | 1 | 1996 | 16 | 0.010 |
Why?
|
Calcium | 1 | 1996 | 34 | 0.010 |
Why?
|
Age of Onset | 1 | 1995 | 79 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 1999 | 255 | 0.010 |
Why?
|
Intrauterine Device Expulsion | 1 | 1994 | 5 | 0.010 |
Why?
|
Renal Circulation | 1 | 1993 | 1 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 1993 | 10 | 0.010 |
Why?
|